Tests inavolisib with Phesgo in HER2-positive, PIK3CA-mutated advanced breast cancer
Tests inavolisib plus Phesgo as maintenance in adults with HER2-positive, PIK3CA-mutated advanced breast cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Key facts
- Where
- Amberg, Berlin, Bottrop, Duesseldorf, Erfurt, Erlangen, Freiburg Im Breisgau, Muenster, Munich, Saarbruecken, and Ulm, GermanySee the 11 sites
- Phase
- Phase 3
Where in Germany
- Klinikum St. Marien AmbergAmberg, GermanyTaking people
- HELIOS Klinikum Berlin Buch GmbHBerlin, GermanyTaking people
- Knappschaft Kliniken Bottrop GmbHBottrop, GermanyTaking people
- Gynonco DuesseldorfDuesseldorf, GermanyTaking people
- Dr. Apel Medizinische Versorgung GmbHErfurt, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Praxis Fuer Interdisziplinaere Onkologie And Haematologie GbRFreiburg Im Breisgau, GermanyTaking people
- Medizinisches Versorgungszentrum MediaVita GmbH MuensterMuenster, GermanyTaking people
- Klinikum Der Universitat Munchen AöRMunich, GermanyTaking people
- Caritas Tragergesellschaft Saarbruecken mbH (cts)Saarbruecken, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT05894239EU 2022-502046-28-00
- Record updated
- 16 October 2026
- Original description
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).Read full original descriptionShow less
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Inclusion: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1; Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection; Confirmation of HER2 biomarker eligibility based on valid results from central testing of tumor tissue documenting HER2-positivity; Confirmation of PIK3CA-mutation biomarker eligibility based on valid results from central testing of tumor tissue documenting PIK3CA-mutated tumor status; Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of >= 6 months; LVEF (left ventricular ejection fraction) of at least 50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA); Adequate hematologic and organ function prior to initiation of study treatment.
Exclusion: Prior treatment in the locally advanced or metastatic setting with any PI3K, AKT, or mTOR inhibitor or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway; Any prior systemic non-hormonal anti-cancer therapy for locally advanced or metastatic HER2-positive breast cancer prior to initiation of induction therapy; Disease progression within 6 months of receiving any HER2-targeted therapy; Serious infection requiring IV antibiotics within 7 days prior to Day 1 of Cycle 1; Any concurrent ocular or intraocular condition that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition; History or active inflammatory bowel disease; Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes; Participants with active HBV infection; Clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis; Symptomatic active lung disease, including pneumonitis or interstitial lung disease; Any history of leptomeningeal disease or carcinomatous meningitis; Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye.